Mesa Laboratories (NASDAQ:MLAB) Director Purchases $252,805.00 in Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB) Director Shiraz Shabanali Ladiwala purchased 3,500 shares of the stock in a transaction on Tuesday, March 10th. The shares were acquired at an average cost of $72.23 per share, for a total transaction of $252,805.00. Following the transaction, the director owned 8,523 shares of the company’s stock, valued at approximately $615,616.29. The trade was a 69.68% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Mesa Laboratories Price Performance

NASDAQ:MLAB opened at $77.81 on Friday. Mesa Laboratories, Inc. has a 12-month low of $55.45 and a 12-month high of $131.20. The firm has a market capitalization of $429.51 million, a price-to-earnings ratio of 121.58 and a beta of 0.85. The stock’s 50 day moving average price is $87.39 and its two-hundred day moving average price is $78.22. The company has a quick ratio of 1.45, a current ratio of 1.94 and a debt-to-equity ratio of 0.86.

Mesa Laboratories (NASDAQ:MLAB) last posted its earnings results on Tuesday, February 3rd. The medical instruments supplier reported $3.07 earnings per share for the quarter, topping analysts’ consensus estimates of $2.41 by $0.66. Mesa Laboratories had a return on equity of 22.02% and a net margin of 1.51%.The business had revenue of $65.13 million for the quarter, compared to analyst estimates of $63.23 million. On average, analysts anticipate that Mesa Laboratories, Inc. will post 8 earnings per share for the current year.

Mesa Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 16th. Shareholders of record on Saturday, February 28th will be given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend is Friday, February 27th. Mesa Laboratories’s payout ratio is 100.00%.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. raised its position in Mesa Laboratories by 5,366.7% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 322 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Mesa Laboratories in the 4th quarter valued at $27,000. Farther Finance Advisors LLC increased its stake in shares of Mesa Laboratories by 17,733.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 535 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 532 shares during the last quarter. CWM LLC increased its stake in shares of Mesa Laboratories by 48.9% in the 3rd quarter. CWM LLC now owns 597 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 196 shares during the last quarter. Finally, Kestra Advisory Services LLC acquired a new position in shares of Mesa Laboratories during the 4th quarter worth $55,000. 90.60% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently issued reports on MLAB. Wall Street Zen upgraded shares of Mesa Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 7th. Weiss Ratings reiterated a “sell (d)” rating on shares of Mesa Laboratories in a research note on Thursday, January 22nd. Wells Fargo & Company increased their price target on shares of Mesa Laboratories from $83.00 to $94.00 and gave the company an “equal weight” rating in a report on Wednesday, February 4th. Finally, Zacks Research upgraded shares of Mesa Laboratories from a “strong sell” rating to a “hold” rating in a research report on Friday, January 9th. Two research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Mesa Laboratories has a consensus rating of “Reduce” and a consensus price target of $94.00.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.